advertisement
Abstract #47865 Published in IGR 13-4
Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
Mizoguchi T; Ozaki M; Wakiyama H; Ogino NClinical Ophthalmology 2011; 5: 1515-1520
Purpose: To evaluate the intraocular pressure (IOP)-lowering effect of adding dorzolamide 1.0%/timolol 0.5% fixed combination (DTFC) to prostaglandin analogs (PGAs) as monotherapy in patients with normal tension glaucoma. Methods: A prospective, clinical, case-controlled study of patients with normal tension glaucoma. Patients had been on a once-daily night dose of prostaglandins (PGs) as monotherapy and then received DTFC added to PGs for 8 weeks. The IOP was measured at 9 am, week 0 (baseline), week 4, and week 8. Results: The baseline IOP of 40 patients who had previously been treated by prostaglandin monotherapy was 15.6 (plus or minus) 2.0 mmHg at baseline. The IOPs at 4 and 8 weeks after adding DTFC to PGs were 13.5 (plus or minus) 2.1 mmHg and 13.7 (plus or minus) 2.2 mmHg, respectively. Significant decrease of the IOP was observed at each time point of measurement as compared with the baseline IOP before adding DTFC (P = 0.01). The percent IOP reduction from the baseline IOP at week 4 and week 8 was 13.5% (plus or minus) 12.3% and 11.7% (plus or minus) 13.1%, respectively. The percentage of patients who achieved 10% or more IOP reduction from the baseline IOP at week 8 was 62.5%. The baseline IOP was significantly correlated with the percent IOP reduction at week 8 (P = 0.03, r = 0.34). Conclusion: DTFC therapy added to PGAs as glaucoma monotherapy is effective in patients with normal tension glaucoma. (copyright) 2011 Mizoguchi et al.
T. Mizoguchi. Mizoguchi Eye Clinic, 6-13 Tawara-machi, Sasebo Nagasaki, 857-0016, Japan. Email: t-mizo@siren.ocn.ne.jp
Classification:
9.2.4 Normal pressure glaucoma (Part of: 9 Clinical forms of glaucomas > 9.2 Primary open angle glaucomas)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
